Michael B. Dwinell, PhD

Professor; Founding Director, Center for Immunology; Director, Bobbie Nick Voss Laboratory for Colon Cancer Research; Hanis-Stepka-Rettig Endowed Chair in Cancer Research

Locations

Microbiology & Immunology
TBRC C3860

Contact Information

General Interests

Cancer Metastasis, Tumor Microenvironment, Mucosal Inflammation

Education

PhD, GI Pathophysiology, University of Wisconsin, Madison, 1996

Learn more about the Dwinell Lab

Biography

Dr. Dwinell, Hanis-Stepka-Rettig Endowed Chair in Cancer Research, is the Founding Director of the Center for Immunology following its inception in 2018. He has completed an MCW executive leadership training program at the Sheldon Lubar School of Business at the University of Wisconsin-Milwaukee as well as the Leadership for Social Inclusion & Equity Workshop developed by the National Coalition Building Institute. He has served on numerous NIH review panels and is currently chair of the Tumor Microenvironment study section.

Dr. Dwinell’s laboratory uses innovative strategies to reprogram the immune microenvironment to overcome immune suppression and evasion in pancreatic cancer. Specifically, his grant supported research examines chemokines as pivotal immune messengers regulating the tumor immune microenvironment. Dr. Dwinell oversees the immunology curriculum in Infectious Agents and Host Immunity and is past Director for Gastrointestinal & Nutritional Pathophysiology in the MCW medical school. He is course director of Mucosal Immunity and teaches in the Foundations in Biomedical Sciences and several other graduate school courses. He has frequently been named an Outstanding Medical Student and Outstanding Graduate Student Teacher and was recognized with the MCW Outstanding Mentor award in 2018.

Research Experience

Adjuvants, Immunologic
Carcinoma, Pancreatic Ductal
Cell Line, Tumor
Cell Movement
Cell Proliferation
Chemokines
Cytokines
Energy Metabolism
Immunity, Mucosal
Immuno-Oncology
Inflammation
Mice

Research Interests

My research interests currently focus on mechanisms tumor progression including remodeling the immune microenvironment. I use a variety of cellular, biochemical, and preclinical approaches to study the mechanisms immune-cancer cell communication essential for cancer progression.

The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.

(Jørgensen AS, Brandum EP, Mikkelsen JM, Orfin KA, Boilesen DR, Egerod KL, Moussouras NA, Vilhardt F, Kalinski P, Basse P, Chen YH, Yang Z, Dwinell MB, Volkman BF, Veldkamp CT, Holst PJ, Lahl K, Goth CK, Rosenkilde MM, Hjortø GM.) Cell Mol Life Sci. 2021 Nov;78(21-22):6963-6978 PMID: 34586443 PMCID: PMC8558179 SCOPUS ID: 2-s2.0-85116031161 09/30/2021
Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.

(Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P.) Cancer Res. 2021 10 15;81(20):5336-5352 PMID: 34380633 PMCID: PMC8530981 SCOPUS ID: 2-s2.0-85116424540 08/13/2021
Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression.

(AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB.) iScience. 2021 Jun 25;24(6):102653 PMID: 34189432 PMCID: PMC8220235 07/01/2021
Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.

(Xin G, Chen Y, Topchyan P, Kasmani MY, Burns R, Volberding PJ, Wu X, Cohn A, Chen Y, Lin CW, Ho PC, Silverstein R, Dwinell MB, Cui W.) Cancer Immunol Res. 2021 04;9(4):454-469 PMID: 33579728 PMCID: PMC8137571 SCOPUS ID: 2-s2.0-85104420312 02/14/2021
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance.

(Parashar D, Geethadevi A, McAllister D, Ebben J, Peterson FC, Jensen DR, Bishop E, Pradeep S, Volkman BF, Dwinell MB, Chaluvally-Raghavan P, James MA.) NPJ Precis Oncol. 2021 Mar 02;5(1):16 PMID: 33654182 PMCID: PMC7925570 SCOPUS ID: 2-s2.0-85109651282 03/04/2021
Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks.

(Urrutia G, de Assuncao TM, Mathison AJ, Salmonson A, Kerketta R, Zeighami A, Stodola TJ, Adsay V, Pehlivanoglu B, Dwinell MB, Zimmermann MT, Iovanna JL, Urrutia R, Lomberk G.) Front Cell Dev Biol. 2021;9:681153 PMID: 34249932 PMCID: PMC8261250 SCOPUS ID: 2-s2.0-85116952280 07/13/2021
STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.

(Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58 PMID: 33548597 PMCID: PMC8081932 SCOPUS ID: 2-s2.0-85104314508 02/07/2021
p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis.

(Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons Bach R, Fu L, Chen G.) Cancer Res. 2020 08 15;80(16):3251-3264 PMID: 32580961 SCOPUS ID: 2-s2.0-85089787021 06/26/2020
Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21.

(Moussouras NA, Hjortø GM, Peterson FC, Szpakowska M, Chevigné A, Rosenkilde MM, Volkman BF, Dwinell MB.) Biochemistry. 2020 04 07;59(13):1338-1350 PMID: 32182428 PMCID: PMC7307649 SCOPUS ID: 2-s2.0-85083041593 03/18/2020
Increased formation of reactive oxygen species during tumor growth: Ex vivo low-temperature EPR and in vivo bioluminescence analyses.

(Cheng G, Pan J, Podsiadly R, Zielonka J, Garces AM, Dias Duarte Machado LG, Bennett B, McAllister D, Dwinell MB, You M, Kalyanaraman B.) Free Radic Biol Med. 2020 02 01;147:167-174 PMID: 31874251 PMCID: PMC6948008 SCOPUS ID: 2-s2.0-85076857582 12/25/2019
Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells.

(Cheng G, Hardy M, Zielonka J, Weh K, Zielonka M, Boyle KA, Abu Eid M, McAllister D, Bennett B, Kresty LA, Dwinell MB, Kalyanaraman B.) Cancer Treat Res Commun. 2020;25:100210 PMID: 32987287 PMCID: PMC7883397 SCOPUS ID: 2-s2.0-85091576205 09/29/2020
Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators.

(Cheng G, Zielonka J, Hardy M, Ouari O, Chitambar CR, Dwinell MB, Kalyanaraman B.) Oncotarget. 2019 May 28;10(37):3518-3532 PMID: 31191823 PMCID: PMC6544408 06/14/2019

Michael B. Dwinell, PhD